Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02771574 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric Hypoglycemia
A Phase 2 study, sponsored by Tracey McLaughlin.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT02771574 is a Phase 2 study that has completed, run by Tracey McLaughlin. The registered enrollment target is 19 participants.
The verdict
NCT02771574, a Phase 2 study, has completed, sponsored by Tracey McLaughlin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study is designed to evaluate the efficacy, safety and pharmacokinetics of subcutaneous exendin (9-39) in subjects with post-bariatric hypoglycemia. Development of this subcutaneous formulation of exendin (9-39) would represent a targeted therapeutic approach for this rare disease with unmet clinical need.
Interventions
- DRUG Lyo avexitide
- DRUG Liq avexitide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-05 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02771574
The ClinicalTrials.gov registry entry for NCT02771574 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tracey McLaughlin, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lyo avexitide is the first listed.
NCT02771574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02771574 about?
NCT02771574 is a clinical study titled "Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric Hypoglycemia". This study is designed to evaluate the efficacy, safety and pharmacokinetics of subcutaneous exendin (9-39) in subjects with post-bariatric hypoglycemia. Development of this subcutaneous formulation of exendin (9-39) would represent a targeted therapeutic approach for this rare disease with unmet cl...
What is the current status of trial NCT02771574?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2016-05. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02771574?
The interventions under investigation include: Lyo avexitide (DRUG), Liq avexitide (DRUG).
Who is sponsoring clinical trial NCT02771574?
This trial is sponsored by Tracey McLaughlin, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.